Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Article

Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue

  1. Vanessa P. Houde1,
  2. Sophie Brûlé1,
  3. William T. Festuccia2,
  4. Pierre-Gilles Blanchard2,
  5. Kerstin Bellmann1,
  6. Yves Deshaies2 and
  7. André Marette1
  1. 1Department of Medicine, Faculty of Medicine, Cardiology Axis of the Quebec Heart and Lung Institute, and the Metabolism, Vascular and Renal Health Axis, Laval University Hospital Research Center, Laval University, Quebec, Canada; and
  2. 2Department of Medicine, Faculty of Medicine, Obesity-Metabolism Axis of the Quebec Heart and Lung Institute, Laval University, Quebec, Canada.
  1. Corresponding author: André Marette, andre.marette{at}crchul.ulaval.ca.
  1. V.P.H. and S.B. contributed equally to this study.

Diabetes 2010 Jun; 59(6): 1338-1348. https://doi.org/10.2337/db09-1324
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • FIG. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Chronic rapamycin treatment decreases adiposity. Sprague-Dawley rats were treated with vehicle or rapamycin (2 mg/kg/day) for 15 days. A: Relative retroperitoneal fat weight. Total DNA tissue content and adipocyte diameter (μm) (B) and representative images of retroperitoneal fat (C) from control and rapamycin-treated rats (magnification ×10) D: Representative Western blots of adipose tissue lysates are shown for phosphorylated S6 (Ser240/244), Akt (Ser473 and Thr308), GSK-3α/β (Ser21/9), and total proteins (two representative animals of six). The graphs depict densitometric analysis of normalization of phospho-Akt/Akt protein. E: Adipose tissue proteins (500 μg) were immunoprecipitated with total Akt antibody. Immunoprecipitates were analyzed for Akt activity. The graphs depict densitometric analysis of total Akt activity. n = 6 for each group. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. CTRL, control; RAP, rapamycin.

  • FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Chronic rapamycin treatment coordinately downregulates genes required for triglyceride hydrolysis, fatty acid transport, and esterification in adipose tissue. Rats were treated with rapamycin as described in the legend to Fig. 1, and adipose tissue was sampled and processed as described in the research design and methods section for determinations of LPL, FATP1, FAT/CD36, Lipin1, PEPCK, MGL, HSL, ATGL, PPARγ1, and PPARγ2 mRNA expression. The graphs depict mRNA expression in the adipose tissue of target genes corrected for the expression of 36B4 as a control gene. n = 12 for each group. *P ≤ 0.05, **P ≤ 0.01.

  • FIG. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Chronic rapamycin treatment induces glucose and insulin intolerance in rats. Rats were treated with rapamycin as described in the legend to Fig. 1 and fasted for 6 h before intraperitoneal tolerance tests. Plasma glucose (A) and insulin levels (B) were measured during a glucose tolerance test. C: Plasma glucose levels were measured during an insulin tolerance test. n = 12 for each group. Black squares: CTRL; white squares: RAP. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

  • FIG. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Chronic rapamycin treatment impairs β-cell mass and insulin clearance in rats. Rats were treated with rapamycin as described in the legend to Fig. 1. Pancreatic sections were stained with an antibody against insulin for the determination of islet size and β-cell mass as described in the research design and methods section. A: Size distribution of islets expressed as percentage of total islets. n = 10 for each group. B: Pancreatic β-cell mass. n = 6 for each group. C: Plasma C-peptide levels. n = 12. D: Ratio of insulin over C-peptide, a measure of insulin clearance. n = 12 for each group. E: Insulin secretion was determined in MIN6 cells treated with rapamycin (25 nmol/l; white squares) or vehicle (black squares) for 24 h followed by glucose stimulation (10 mmol/l) for various time points. n = 3 independent experiments. *P ≤ 0.05, ***P ≤ 0.001.

  • FIG. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Chronic rapamycin treatment induces glucose intolerance by upregulating gluconeogenesis in rats. Rats were treated with rapamycin as described in the legend to Fig. 1. A: G6Pase, PEPCK, and PGC-1α mRNA expression. The graphs depict mRNA expression in the liver of target genes corrected for the expression of 36B4 as a control gene. B: Representative Western blots of PGC-1, FoxO1, CRTC2, and CREB proteins in nuclear extracts prepared from liver samples (two representative animals of six are shown). The graphs depict densitometric analysis of normalization of total protein/Histone H1 protein. n = 6 for each group. C: Plasma glucose levels measured during a pyruvate tolerance test on rats fasted for 12 h followed by 3 h of refeeding. n = 6 for each group. Black squares: CTRL; white squares: RAP. *P ≤ 0.05, **P ≤ 0.01.

  • FIG. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Chronic rapamycin treatment improves insulin signaling in liver and muscle. Rats were treated with rapamycin as described in the legend to Fig. 1. A: Representative Western blots of liver lysates are shown for phosphorylated S6 (Ser240/244) and phospho-tyrosine on IRS-1 or IRS-2 immunoprecipitates (1 mg) (two representative animals of six). The graphs depict densitometric analysis of normalization of phospho-tyrosine/IRS protein. B: Representative Western blots of phosphorylated IRS-1 (Ser1101 and Ser636/639) and total proteins (two representative animals of six are shown) in liver lysates. The graphs depict densitometric analysis of normalization of phospho-IRS-1/IRS-1 protein. C: Representative Western blots of total IRS-1 and IRS-2 protein in liver lysates. The graphs depict densitometric analysis of normalization of total IRS/Actin. D: Equal amounts of liver protein (1 mg) were immunoprecipitated with IRS-1 and IRS-2 antibodies. Immunoprecipitates were analyzed for PI 3-kinase activity. The graphs depict densitometric analysis of IRS-1– and IRS-2–associated PI 3-kinase activity. E: Representative Western blots of liver lysates are shown for phosphorylated Akt (Ser473 and Thr308) and total proteins (two representative animals of six). The graphs depict densitometric analysis of normalization of phospho-Akt/Akt protein. F: Liver proteins (500 μg) were immunoprecipitated with total Akt antibody. Immunoprecipitates were analyzed for Akt activity. The graphs depict densitometric analysis of total Akt activity. G: Representative Western blots of muscle lysates are shown for phospho-tyrosine on IRS-1 immunoprecipitates (1 mg). The graphs depict densitometric analysis of IRS-1 phospho-tyrosine corrected for IRS-1 protein content. n = 6 animals. H: Muscle proteins (500 μg) were immunoprecipitated with total Akt antibody. Immunoprecipitates were analyzed for Akt activity and the graph depicts the densitometric analysis of several independent determinations. n = 6 for each group. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

Tables

  • Figures
  • TABLE 1

    Effect of 15-day rapamycin treatment on weight, food intake, and metabolic parameters of treated rats

    ControlRapamycin
    Body weight (g)303.6 ± 3.68226.3 ± 4.34***
    Weight gain (g)91.4 ± 3.5712.8 ± 3.87***
    Food intake (g)256.4 ± 6.53217.7 ± 8.53**
    Food efficiency (body weight gain/food intake)0.117 ± 0.0040.019 ± 0.006***
    Glucose (mmol/l)8.5 ± 0.3313.3 ± 2.53*
    Insulin (pmol/l)351.5 ± 58.71,265.1 ± 395.1*
    Glucagon (ng/l)127.25 ± 10.65130.47 ± 14.33
    Triglycerides (mmol/l)0.644 ± 0.0500.848 ± 0.060*
    NEFAs (mmol/l)0.115 ± 0.0200.190 ± 0.040*
    Glycerol (mg/dl)1.025 ± 0.0841.177 ± 0.107
    Lactate (mmol/l)0.904 ± 0.0500.852 ± 0.039
    Adiponectin (μg/ml)11.89 ± 1.5312.11 ± 0.83
    Leptin (ng/ml)9.48 ± 1.864.94 ± 1.51*
    • Data are average ± SE (n = 12 control, n = 10 for rapamycin). Refed plasma data are average ± SE (n = 6–12 for control, n = 6–10 for rapamycin).

    • *P ≤ 0.05,

    • **P ≤ 0.01,

    • ***P ≤ 0.001 vs. control. NEFAs, nonesterified fatty acids.

  • TABLE 2

    Effect of 15-day rapamycin treatment on muscle and liver triglycerides

    ControlRapamycin
    Muscle triglycerides (mmol/g tissue)9.52 ± 0.9210.40 ± 0.93
    Liver triglycerides (mmol/g tissue)18.69 ± 4.0212.94 ± 0.95
    • Data are average ± SE (n = 6 for each group).

PreviousNext
Back to top

In this Issue

June 2010, 59(6)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Vanessa P. Houde, Sophie Brûlé, William T. Festuccia, Pierre-Gilles Blanchard, Kerstin Bellmann, Yves Deshaies, André Marette
Diabetes Jun 2010, 59 (6) 1338-1348; DOI: 10.2337/db09-1324

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Vanessa P. Houde, Sophie Brûlé, William T. Festuccia, Pierre-Gilles Blanchard, Kerstin Bellmann, Yves Deshaies, André Marette
Diabetes Jun 2010, 59 (6) 1338-1348; DOI: 10.2337/db09-1324
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Article

  • An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes
  • Loss of Prohibitin Induces Mitochondrial Damages Altering β-Cell Function and Survival and Is Responsible for Gradual Diabetes Development
  • Cbl-b Is a Critical Regulator of Macrophage Activation Associated With Obesity-Induced Insulin Resistance in Mice
Show more Original Article

Metabolism

  • Role of the Neutral Amino Acid Transporter SLC7A10 in Adipocyte Lipid Storage, Obesity, and Insulin Resistance
  • Heme Oxygenase-1 Regulates Ferrous Iron and Foxo1 in Control of Hepatic Gluconeogenesis
  • Ncor2/PPARα-Dependent Upregulation of MCUb in the Type 2 Diabetic Heart Impacts Cardiac Metabolic Flexibility and Function
Show more Metabolism

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.